DiaMedica Therapeutics Inc

(NASDAQ:DMAC)

Latest On DiaMedica Therapeutics Inc (DMAC):

Date/Time Type Description Signal Details
2023-05-16 12:52 ESTNewsDiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call TranscriptN/A
2023-03-29 11:42 ESTNewsDiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call TranscriptN/A
2023-03-28 21:07 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.52 in-lineN/A
2022-11-30 16:32 ESTNewsDiaMedica: What's Happened And What's The Value HereN/A
2022-11-09 23:13 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03N/A
2022-10-27 07:45 ESTNewsDiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trialN/A
2022-08-12 01:34 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 08:38 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.05N/A
2022-07-06 21:27 ESTNewsFDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical holdN/A
2022-05-16 11:12 ESTNewsDiaMedica Therapeutics Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-07 00:58 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-05 02:30 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.07N/A
2022-03-15 22:19 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-15 02:31 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.65 beats by $0.08N/A
2022-01-05 20:09 ESTNewsDiaMedica Therapeutics appoints chief medical officerN/A
2021-11-12 00:43 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-06 00:33 ESTNewsDiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.N/A
2021-09-30 13:30 ESTNewsDiaMedica gets FDA Fast Track status for acute ischemic stroke treatment DM199N/A
2021-09-27 16:22 ESTNewsDiaMedica Therapeutics to undertake $30M private equity offeringN/A
2021-09-21 16:39 ESTNewsDiaMedica Therapeutics (DMAC) Investor Presentation - SlideshowN/A
2021-08-12 15:59 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-11 19:36 ESTNewsDiaMedica Therapeutics EPS beats by $0.05N/A
2021-07-21 05:39 ESTNewsDiaMedica: Undercovered Stroke Drug Company With Decent DataN/A
2021-07-21 05:17 ESTNewsDiamedica shows mixed results for kidney disease therapy in mid-stage studyN/A
2021-07-21 04:53 ESTNewsDiaMedica Therapeutics adds two industry veterans to its board of directorsN/A
2021-05-06 10:44 ESTNewsDiaMedica Therapeutics reports Q1 resultsN/A
2021-03-18 12:32 ESTAnalyst RatingThe Analyst Target Price has increased from $20.67 to $22.17.Buy
2021-03-12 11:29 ESTAnalyst RatingThe Analyst Target Price has increased from $19.83 to $20.67.Buy
2021-03-12 02:43 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-11 15:30 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 11:29 ESTEarnings EstimateAn EPS average of -$1.19 is estimated for the 2022 year.Sell
2021-03-11 11:29 ESTEarnings EstimateAn EPS average of -$0.76 is estimated for the 2021 year.Sell
2021-03-11 11:29 ESTEarnings EstimateAn EPS average of -$0.19 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 06:01 ESTNewsDiaMedica Therapeutics EPS misses by $0.06N/A
2021-02-18 11:27 ESTAnalyst RatingThe Analyst Target Price has increased from $16.2 to $19.83.Buy
2021-01-05 11:39 ESTAnalyst RatingThe Analyst Target Price has increased from $13.4 to $16.2.Buy
2020-12-17 11:47 ESTEarnings EstimateAn EPS average of -$0.13 is estimated for the quarter ending on March 31, 2021.Buy
2020-12-17 11:47 ESTEarnings EstimateAn EPS average of -$0.16 is estimated for the quarter ending on December 31, 2020.Buy
2020-12-17 11:47 ESTAnalyst RatingThe Analyst Target Price has increased from $0 to $13.4.Buy
2020-12-10 10:57 ESTNewsDiaMedica rises 6% on successful Type B meeting with FDA for DM199 study in acute ischemic strokeN/A
2020-11-26 19:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 19:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 07:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 05:35 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-07 15:37 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 11:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 07:04 ESTNewsDiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call PresentationN/A
2020-11-05 03:04 ESTNewsDiaMedica Therapeutics EPS misses by $0.04N/A
2020-09-26 12:34 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:42 ESTFinancialsCompany financials have been released.Neutral

About DiaMedica Therapeutics Inc (DMAC):

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC Quotes by TradingView

See Advanced Chart

General

  • Name DiaMedica Therapeutics Inc
  • Symbol DMAC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Last Split Factor1:20
  • Last Split Date2018-11-15
  • Fiscal Year EndDecember
  • IPO Date2008-01-04
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.diamedica.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 7.28
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.79
  • Next Year EPS Estimate -$1.30
  • Next Quarter EPS Estimate -$0.19
  • Return on Assets -43%
  • Return on Equity -73%
  • Earnings Per Share -$0.90
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 180.81 million
  • EBITDA -9387000
  • Analyst Target Price $22.17
  • Book Value Per Share $1.39
View More

Share Statistics

  • Shares Outstanding 18.78 million
  • Shares Float 16.41 million
  • % Held by Insiders 672%
  • % Held by Institutions 39.31%
  • Shares Short 116640
  • Shares Short Prior Month 82969
  • Short Ratio 0.7
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 2.43
  • 52 Week High $10.88
  • 52 Week Low $1.87
  • 50 Day Moving Average 9.19
  • 200 Day Moving Average 6.69
View More

Dividends

  • Dividend Date 2018-11-15
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

DiaMedica Therapeutics Inc (DMAC) Dividend Calendar:

DMAC's last dividend payment was made to shareholders on November 15, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

DiaMedica Therapeutics Inc (DMAC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$N/A-$0.23-$0.16-41.54%
2020-09-302020-11-04$N/A-$0.19-$0.15-29.52%
2020-06-302020-08-11$N/A-$0.17-$0.14-25.93%
2020-03-312020-05-13$N/A-$0.19-$0.2933.33%
2019-12-312020-03-23$N/A-$0.21-$0.2516%
2019-09-302019-11-13$N/A-$0.20-$0.214.76%
2019-06-302019-08-13$N/A-$0.21-$0.2618.19%
2019-03-312019-05-13$N/A-$0.27-$0.20-35%
2018-12-312019-03-19$-3657-$0.11-$0.2657.69%
2018-09-302018-12-10$503657-$0.07
2018-06-302018-08-30$N/A-$0.46
2018-03-312018-04-30$N/A-$0.09
2017-09-302017-11-27$N/A-$0.15
2017-06-302017-08-29$N/A-$0.18
2017-03-312017-04-27$N/A-$0.24
2016-09-302016-11-29$N/A-$0.20
2016-06-302016-08-29$N/A-$0.12
2016-03-312016-04-29$N/A-$0.08
2015-09-302015-11-30$N/A-$0.07
2015-06-302015-08-31$N/A-$0.10
2015-03-312015-04-30$N/A-$0.14
2014-09-302014-11-28$N/A-$0.40-$0.20-100%
2014-06-302014-08-28$N/A-$0.40-$0.6033.33%
2014-03-312014-04-30$N/A-$0.40-$0.400%
2013-09-302013-11-28$N/A-$0.47
2013-06-302013-08-28$N/A-$0.80
2013-03-312013-03-31$N/A-$1.08
2012-12-312012-12-31$N/A-$1.25
2012-09-302012-09-30$N/A-$1.02

DiaMedica Therapeutics Inc (DMAC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

DiaMedica Therapeutics Inc (DMAC) Chart:

DiaMedica Therapeutics Inc (DMAC) News:

Below you will find a list of latest news for DiaMedica Therapeutics Inc (DMAC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

DiaMedica Therapeutics Inc (DMAC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-03-212.50CALL0 0314.58TRUE00
2025-03-2150CALL0 0217.61TRUE00
2025-03-217.50.22CALL6 184.96FALSE0.070.47
2025-03-21100CALL0 0163.36FALSE00
2025-03-212.50PUT0 0519.03FALSE00
2025-03-2150.28PUT1 197.76FALSE0.181.8
2025-03-217.51.02PUT1 058.17TRUE1.020
2025-03-21100PUT0 0189.3TRUE00
2025-04-172.53CALL0 11282.84TRUE00
2025-04-1751.96CALL0 19493.2TRUE00
2025-04-177.50.4CALL0 1265.63FALSE00
2025-04-17100CALL0 0101.1FALSE00
2025-04-1712.50.15CALL0 1201.72FALSE00
2025-04-172.50.05PUT0 13166.76FALSE00
2025-04-1750.15PUT0 2479.89FALSE00
2025-04-177.50PUT0 0117.77TRUE00
2025-04-17100PUT0 0199.57TRUE00
2025-04-1712.50PUT0 0217.28TRUE00
2025-07-182.53.45CALL0 2162.41TRUE00
2025-07-1850CALL0 0117.31TRUE00
2025-07-187.50.6CALL0 1472.15FALSE00
2025-07-18100.4CALL0 4100.83FALSE00
2025-07-1812.50CALL0 0135.7FALSE00
2025-07-182.50PUT0 0134.45FALSE00
2025-07-1850PUT0 0140.66FALSE00
2025-07-187.50PUT0 043.22TRUE00
2025-07-18100PUT0 049.75TRUE00
2025-07-1812.50PUT0 0105.37TRUE00
2025-10-172.50CALL0 0110.22TRUE00
2025-10-1750CALL0 072.87TRUE00
2025-10-177.50CALL0 072.02FALSE00
2025-10-17100CALL0 089.27FALSE00
2025-10-1712.50CALL0 072.72FALSE00
2025-10-172.50PUT0 0602.05FALSE00
2025-10-1750PUT0 067.5FALSE00
2025-10-177.50PUT0 059.8TRUE00
2025-10-17100PUT0 093.02TRUE00
2025-10-1712.50PUT0 077.64TRUE00

Latest DMAC Trades:

Date Shares Price
Jun 13, 2022 3:48 PM EST100$2.29

DiaMedica Therapeutics Inc (DMAC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920012348/0001437749-20-012348-index.htm
2020-01-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1401040/000000000020000113/0000000000-20-000113-index.htm
2020-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1401040/000093583620000089/0000935836-20-000089-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000064/0001235802-19-000064-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000065/0001235802-19-000065-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000066/0001235802-19-000066-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000067/0001235802-19-000067-index.htm
2019-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000105/0001235802-19-000105-index.htm
2019-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000106/0001235802-19-000106-index.htm
2019-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000107/0001235802-19-000107-index.htm
2019-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000108/0001235802-19-000108-index.htm
2019-11-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000130/0001235802-19-000130-index.htm
2019-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000131/0001235802-19-000131-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000049/0001235802-20-000049-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/0001235802-20-000050-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000051/0001235802-20-000051-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000052/0001235802-20-000052-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000053/0001235802-20-000053-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000054/0001235802-20-000054-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000055/0001235802-20-000055-index.htm
2020-01-31SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1401040/000138713120000815/0001387131-20-000815-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774919016566/0001437749-19-016566-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774919016595/0001437749-19-016595-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774919020938/0001437749-19-020938-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774919022681/0001437749-19-022681-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774919022682/0001437749-19-022682-index.htm
2020-01-02S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1401040/000143774920000070/0001437749-20-000070-index.htm
2020-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920000102/0001437749-20-000102-index.htm
2020-01-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1401040/000143774920000296/0001437749-20-000296-index.htm
2020-02-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920002238/0001437749-20-002238-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920002240/0001437749-20-002240-index.htm
2020-02-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920002327/0001437749-20-002327-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920002598/0001437749-20-002598-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920005905/0001437749-20-005905-index.htm
2020-03-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1401040/000143774920005906/0001437749-20-005906-index.htm
2020-04-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1401040/000143774920007997/0001437749-20-007997-index.htm
2020-04-20DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1401040/000143774920007998/0001437749-20-007998-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920010597/0001437749-20-010597-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920010599/0001437749-20-010599-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920012348/0001437749-20-012348-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920016682/0001437749-20-016682-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920016685/0001437749-20-016685-index.htm
2020-08-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920017103/0001437749-20-017103-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920017105/0001437749-20-017105-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920017512/0001437749-20-017512-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920017514/0001437749-20-017514-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920022536/0001437749-20-022536-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920022537/0001437749-20-022537-index.htm
2020-01-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1401040/999999999520000060/9999999995-20-000060-index.htm

DiaMedica Therapeutics Inc (DMAC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of DiaMedica Therapeutics Inc (DMAC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 672%
Institutional Ownership: 3931%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-08-19Scott KellenCFO and SecretaryBuy3,000.002.437,290.0010,290.00https://www.sec.gov/Archives/edgar/data/1401040/000123580219000108/0001235802-19-000108-index.htm
2020-06-01James T. ParsonsDirectorBuy8,102.004.5937,188.1814,202.00https://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/0001235802-20-000050-index.htm
2019-08-16Dietrich John PaulsPresident and CEOBuy1,000.002.682,676.9030,804.00https://www.sec.gov/Archives/edgar/data/1401040/000123580219000105/0001235802-19-000105-index.htm
2019-08-16Richard D. PilnikDirectorBuy7,840.002.5620,039.0450,678.00https://www.sec.gov/Archives/edgar/data/1401040/000123580219000107/0001235802-19-000107-index.htm
2020-06-01Richard D. PilnikDirectorBuy10,168.004.5946,671.1260,846.00https://www.sec.gov/Archives/edgar/data/1401040/000123580220000049/0001235802-20-000049-index.htm
2019-08-16HARRY W JR ALCORNChief Medical OfficerBuy7,260.002.6719,365.328,260.00https://www.sec.gov/Archives/edgar/data/1401040/000123580219000106/0001235802-19-000106-index.htm
2020-06-01Randall Michael GiuffreDirectorBuy7,784.004.5935,728.5693,588.00https://www.sec.gov/Archives/edgar/data/1401040/000123580220000051/0001235802-20-000051-index.htm